ACHILLES THERAPEUTICS PL-ADR (ACHL) Stock Price, Quote, News and Overview
NASDAQ:ACHL - Nasdaq - US00449L1026 - ADR - Currency: USD
ACHL Quote, Performance and Key Statistics
1.39
0 (0%)
The current stock price of ACHL is 1.39 USD. In the past year, price increased by 13.01%.
ACHL Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About ACHL
Company Profile
Achilles Therapeutics Plc is a biopharmaceutical company engages in developing transformative precision T-cell therapies to treat multiple types of solid tumors. The firm is engaged in developing precision T cell therapies to treat multiple types of solid tumors. Its lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Its pipeline includes Chiron: Advanced Non-Small Cell Lung Cancer, Thetis: Melanoma (Monotherapy), Thetis: Melanoma (PD-1 Combination), and other indications. The company is focused on advancing cancer therapies through its work in the field of tumor evolution. Its platform enables to identify mutations formed early in the development of a cancer that give rise to antigens that are expressed by all of a patient's cancer cells but are absent from healthy tissue. The company refers to this class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, it has developed a bioinformatic platform called PELEUS.
Company Info
ACHILLES THERAPEUTICS PL-ADR
245 Hammersmith Road, Gunnels Wood Road
London W6 8PW GB
CEO: Iraj Ali
Employees: 204
Company Website: https://www.achillestx.com/
Investor Relations: https://ir.achillestx.com/
Phone: 442081544600
ACHILLES THERAPEUTICS PL-ADR / ACHL FAQ
What is the stock price of ACHILLES THERAPEUTICS PL-ADR today?
The current stock price of ACHL is 1.39 USD.
What is the ticker symbol for ACHILLES THERAPEUTICS PL-ADR stock?
The exchange symbol of ACHILLES THERAPEUTICS PL-ADR is ACHL and it is listed on the Nasdaq exchange.
On which exchange is ACHL stock listed?
ACHL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ACHILLES THERAPEUTICS PL-ADR stock?
6 analysts have analysed ACHL and the average price target is 6.12 USD. This implies a price increase of 340.29% is expected in the next year compared to the current price of 1.39. Check the ACHILLES THERAPEUTICS PL-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ACHILLES THERAPEUTICS PL-ADR worth?
ACHILLES THERAPEUTICS PL-ADR (ACHL) has a market capitalization of 59.36M USD. This makes ACHL a Micro Cap stock.
How many employees does ACHILLES THERAPEUTICS PL-ADR have?
ACHILLES THERAPEUTICS PL-ADR (ACHL) currently has 204 employees.
What are the support and resistance levels for ACHILLES THERAPEUTICS PL-ADR (ACHL) stock?
ACHILLES THERAPEUTICS PL-ADR (ACHL) has a support level at 1.38 and a resistance level at 1.4. Check the full technical report for a detailed analysis of ACHL support and resistance levels.
Should I buy ACHILLES THERAPEUTICS PL-ADR (ACHL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ACHL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ACHL, evaluating the profitability, health, valuation and growth aspects
- ACHILLES THERAPEUTICS PL-ADR (ACHL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ACHILLES THERAPEUTICS PL-ADR (ACHL) Sales and EPS estimates to see what analysts future expectations are.
- ACHILLES THERAPEUTICS PL-ADR (ACHL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ACHILLES THERAPEUTICS PL-ADR (ACHL) Insider and Institutional Ownership to learn about the owners and their transactions.
- ACHILLES THERAPEUTICS PL-ADR (ACHL) Stock Chart to make your own analysis
- ACHILLES THERAPEUTICS PL-ADR (ACHL) Latest news and press-releases to stay up to date.
Does ACHILLES THERAPEUTICS PL-ADR (ACHL) stock pay dividends?
ACHL does not pay a dividend.
When does ACHILLES THERAPEUTICS PL-ADR (ACHL) report earnings?
ACHILLES THERAPEUTICS PL-ADR (ACHL) will report earnings on 2025-04-02, after the market close.
What is the Price/Earnings (PE) ratio of ACHILLES THERAPEUTICS PL-ADR (ACHL)?
ACHILLES THERAPEUTICS PL-ADR (ACHL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.65).
What is the Short Interest ratio of ACHILLES THERAPEUTICS PL-ADR (ACHL) stock?
The outstanding short interest for ACHILLES THERAPEUTICS PL-ADR (ACHL) is 2% of its float. Check the ownership tab for more information on the ACHL short interest.
ACHL Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ACHL. When comparing the yearly performance of all stocks, ACHL is one of the better performing stocks in the market, outperforming 91.65% of all stocks.
ACHL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACHL. No worries on liquidiy or solvency for ACHL as it has an excellent financial health rating, but there are worries on the profitability.
ACHL Financial Highlights
Over the last trailing twelve months ACHL reported a non-GAAP Earnings per Share(EPS) of -1.65. The EPS increased by 12.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.52% | ||
| ROE | -64.84% | ||
| Debt/Equity | 0 |
ACHL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 40% to ACHL. The Buy consensus is the average rating of analysts ratings from 6 analysts.